Ahmet Sezer, MD, professor, Department of Medical Oncology, Başkent University, Adana, Turkey, discusses the FDA approval of cemiplimab-rwlc (Libtayo) as frontline treatment for patients with advanced non–small cell lung cancer (NSCLC) and high PD-L1 expression.

On February 22, 2021, the FDA approved cemiplimab monotherapy for use as frontline treatment for patients with advanced NSCLC with a PD-L1 expression level of 50% or higher. The regulatory decision was based on findings from the phase 3 EMPOWER-Lung1 trial, in which cemiplimab reduced the risk of death by 32% compared with chemotherapy in patients with a PD-L1 expression of 50% or higher.

Cemiplimab provides another effective option for patients with advanced NSCLC who have high PD-L1 expression, says Sezer. Moreover, findings from the EMPOWER-Lung1 trial have confirmed clinical benefit for this patient population with cemiplimab despite a high crossover rate and broadened inclusion criteria, Sezer explains. However, as advanced NSCLC is a heterogenous disease, additional research efforts are needed to further improve survival for this subset of patients, concludes Sezer.

Ahmet Sezer, MD

Articles

Dr. Sezer on the FDA Approval of Cemiplimab in Frontline Advanced NSCLC With High PD-L1 Expression